95
Views
38
CrossRef citations to date
0
Altmetric
Original Research

PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy

, , &
Pages 2865-2871 | Published online: 06 Jun 2017

References

  • PratJGallardoACuatrecasasMCatasusLEndometrial carcinoma: pathology and geneticsPathology2007391728717365824
  • BenshushanAEndometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatmentEur J Obstet Gynecol Reprod Biol2004117213213715541846
  • MinaguchiTNakagawaSTakazawaYCombined phospho-AKT and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometriumCancer Lett2007248111212216919866
  • HahnHSYoonSGHongJSConservative treatment with progestin and pregnancy outcomes in endometrial cancerInt J Gynecol Cancer20091961068107319820370
  • HoekstraAVKimJJKehPSchinkJCAbsence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case reportJ Reprod Med2008531186987319097521
  • KimJJChapman-DavisERole of progesterone in endometrial cancerSemin Reprod Med2010281819020104432
  • WangSPudneyJSongJMorGSchwartzPEZhengWMechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancerGynecol Oncol2005882108117
  • SaitohMOhmichiMTakahashiKMedroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase⁄AKT⁄nuclear factor-kappaB cascade in human breast cancer cellsEndocrinology2005146114917492516123159
  • CuiXZhangPDengWInsulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase⁄AKT⁄mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancerMol Endocrinol200317457558812554765
  • FujiwaraMIzuishiKSanoTModulating effect of the PI 3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cellsJ Exp Clin Cancer Res2008277619032736
  • SimonciniTGenazzaniARNon-genomic actions of sex steroid hormonesEur J Endocrinol2003148328129212611608
  • HubbardPAMoodyCLMuraliRAllosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunitiesFront Physiol2014547825566081
  • ChiaSGandhiSJoyAANovel agents and associated toxicities of inhibitors of the pI3k/Akt/mtor pathway for the treatment of breast cancerCurr Oncol2015221334825684987
  • MabuchiSKurodaHTakahashiRSasanoTThe PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancerGynecol Oncol2015371173179
  • BecaFAndreRMartinsDSBilhimTMartinsDSchmittFp-mTOR expression is associated with better prognosis in luminal breast carcinomaJ Clin Pathol2014671196196725053543
  • De AmicisFGuidoCSantoroMA novel functional interplay between progesterone receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cellsJ Cell Mol Med201418112252226525216078
  • ZhaoSLiGYangLLiLLiHResponse-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetateOncol Lett20135113914423255909
  • BallareCVallejoGVicentGPSaraguetaPBeatoMProgesterone signaling in breast and cendometriumJ Steroid Biochem Mol Biol20061021–521017070033
  • TakamuraAKomatsuMHaraTAutophagy-deficient mice develop multiple liver tumorsGenes Dev201125879580021498569
  • SobolewskaAGajewskaMZarzyńskaJGajkowskaBMotylTIGF-I, EGF, and sex steroids regulate autophagy in bovine mammary epithelial cells via the mTOR pathwayEur J Cell Biol200988211713019013662
  • ChoiSShinHSongHLimHJSuppression of autophagic activation in the mouse uterus by estrogen and progesteroneJ Endocrinol20142211395024443716
  • KimJKimTYChoKSKimHNKohJYAutophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosisNeurobiol Dis201359808523891729
  • JanzenDMRosalesMAPaikDYProgesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapyCancer Res201373469723744837
  • DavisIDLongAYipSEVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaAnn Oncol20152661118112325701452
  • WolinEMLong-term everolimus treatment of patients with pancreatic neuroendocrine tumorsChemotherapy2015603143150